Akero Therapeutics Newsroom

Akero Therapeutics(AKRO.US) Officer Sells US$3.44 Million in Common Stock

$Akero Therapeutics(AKRO.US)$ Officer Cheng Andrew sold 108.37K shares of common stock on Nov 1, 2024 at an average price of $31.729 for a total value of $3.44 million.Source: Announcement What is

Futu NewsNov 5 22:02

Express News | Madrigal Pharmaceuticals Shares up 11%, Akero Therapeutics Gains 6% and Viking Therapeutics Shares Rise 2%

BreakingsNov 1 21:51

Express News | Shares of Some Liver Disease Drugmakers Rise Between 2% and 11% ; Late-Stage Data From Novo's Weight-Loss Drug Shows Improvement in Fatty Liver Disease

BreakingsNov 1 21:49

Axonis Therapeutics Announces $115 Million Series A Financing

PR NewswireOct 30 18:00

Akero Therapeutics to Present Data Reinforcing the Efficacy of Efruxifermin at the 75th Annual AASLD The Liver Meeting 2024

GlobeNewswireOct 21 19:00

Akero Therapeutics, Inc. (AKRO): A Visionary Small-Cap Stock Pick by Hedge Funds

Yahoo FinanceOct 16 06:10

Akero Therapeutics to Present at the H.C. Wainwright 8th Annual MASH Virtual Conference

GlobeNewswireSep 30 19:00

Akero Therapeutics CDO Sells Shares Worth Over $230,000

InvestingSep 19 09:22

H.C. Wainwright Maintains Akero Therapeutics(AKRO.US) With Buy Rating, Maintains Target Price $50

H.C. Wainwright analyst Ed Arce maintains $Akero Therapeutics(AKRO.US)$ with a buy rating, and maintains the target price at $50.According to TipRanks data, the analyst has a success rate of 44.0%

Futu NewsSep 16 23:31 · Ratings

Oxford Industries Reports Weak Results, Joins Viper Energy And Other Big Stocks Moving Lower In Thursday's Pre-Market Session

BenzingaSep 12 20:02

Wellington Management Group LLP's Strategic Acquisition in Akero Therapeutics Inc

Yahoo FinanceSep 12 13:12

Akero Therapeutics' Promising Phase 3 Programs Bolster Buy Rating

TipRanksSep 10 17:56 · Ratings

Express News | Akero Therapeutics Inc - Phase 2B Symmetry Study Results Expected in Q1 2025

BreakingsSep 9 19:00

Express News | Akero Therapeutics Announces First Patient Dosed in Phase 3 Synchrony Outcomes Study of Efruxifermin in Patients With Compensated Cirrhosis Due to Mash

BreakingsSep 9 19:00

Akero Therapeutics Announces First Patient Dosed in Phase 3 SYNCHRONY Outcomes Study of Efruxifermin in Patients With Compensated Cirrhosis Due to MASH

GlobeNewswireSep 9 19:00

Akero Therapeutics, Inc. (AKRO): This Small-Cap Healthcare Stock Is A Good Buy Right Now

Yahoo FinanceSep 5 12:02

Akero Therapeutics to Present at the Morgan Stanley 22nd Annual Global Healthcare Conference

Market ChameleonAug 29 04:05

Akero Therapeutics Insider Sold Shares Worth $386,714, According to a Recent SEC Filing

MT NewswiresAug 28 23:26

Insiders At Akero Therapeutics Sold US$1.1m In Stock, Alluding To Potential Weakness

Simply Wall StAug 27 20:36

Morgan Stanley Maintains Akero Therapeutics(AKRO.US) With Buy Rating, Maintains Target Price $46

Morgan Stanley analyst Michael Ulz maintains $Akero Therapeutics(AKRO.US)$ with a buy rating, and maintains the target price at $46.According to TipRanks data, the analyst has a success rate of 41.5%

Futu NewsAug 13 20:31 · Ratings